TY - JOUR
T1 - Evaluation of serum-free media formulations in feeder cell–stimulated expansion of natural killer cells
AU - Moseman, Jena E.
AU - Foltz, Jennifer A.
AU - Sorathia, Kinnari
AU - Heipertz, Erica L.
AU - Lee, Dean A.
N1 - Funding Information:
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. This work was conducted as part of a collaborative research agreement with Thermo Fisher Scientific. D.A.L. reports a consulting relationship with Caribou Biosciences and Courier Therapeutics and has equity, performs consulting and chairs the Scientific Advisory Board for Kiadis Pharma. E.L.H. is employed by Thermo Fisher Scientific. The remaining authors have no competing interests to declare. Conception and design of the study: JEM, JAF, ELH, DAL. Acquisition of data: JEM, JAF, KS, ELH. Analysis and interpretation of data: JEM, JAF, ELH, DAL. Drafting or revising the manuscript: JEM, JAF, ELH, DAL. All authors have approved the final article. The authors would like to thank Thermo Fisher Scientific, Miltenyi Biotec, Aurora Biosystems and R&D Systems for generously supplying media for this research study.
Publisher Copyright:
© 2020 International Society for Cell and Gene Therapy
PY - 2020/6
Y1 - 2020/6
N2 - Background: Optimal expansion of therapeutic natural killer (NK) cell products has required media supplementation with human or fetal bovine serum, which raises safety and regulatory concerns for clinical manufacturing. Serum-free media (SFM) have been optimized for T-cell expansion, but few SFM systems have been developed for NK cells. Here, we compare six commercial clinical-grade SFM with our standard fetal bovine serum–containing medium for their ability to support NK cell expansion and function. Methods: Human peripheral blood NK cells were expanded in selected media by recursive weekly stimulation with K562-based feeder cells expressing membrane-bound interleukin-21 and CD137L. Expansion was the primary readout, and the best-performing SFM was then compared with standard medium for cytotoxicity, phenotype, degranulation and cytokine secretion. Multiple lots were compared for consistency, and media was analyzed throughout for nutrient consumption and metabolic byproducts. Results: TexMACS, OpTmizer, SCGM, ABS-001 and StemXVivo demonstrated equal or inferior NK cell expansion kinetics compared with standard medium, but expansion was markedly superior with AIM V + 5% Immune Cell Serum Replacement (ICSR; mean 5448 vs. 2621-fold expansion in 14 days). Surprisingly, NK cells expanded in AIM V + ICSR also showed increased cytotoxicity, tumor necrosis factor α secretion and DNAM-1, NKG2D, NKp30, FasL, granzyme B and perforin expression. Lot-to-lot variability was minimal. Glucose and glutamine consumption were inversely related to lactate and ammonia production. Discussion: The AIM V + ICSR SFM system supports excellent ex vivo expansion of clinical-grade NK cells with the phenotype and function needed for adoptive immunotherapy.
AB - Background: Optimal expansion of therapeutic natural killer (NK) cell products has required media supplementation with human or fetal bovine serum, which raises safety and regulatory concerns for clinical manufacturing. Serum-free media (SFM) have been optimized for T-cell expansion, but few SFM systems have been developed for NK cells. Here, we compare six commercial clinical-grade SFM with our standard fetal bovine serum–containing medium for their ability to support NK cell expansion and function. Methods: Human peripheral blood NK cells were expanded in selected media by recursive weekly stimulation with K562-based feeder cells expressing membrane-bound interleukin-21 and CD137L. Expansion was the primary readout, and the best-performing SFM was then compared with standard medium for cytotoxicity, phenotype, degranulation and cytokine secretion. Multiple lots were compared for consistency, and media was analyzed throughout for nutrient consumption and metabolic byproducts. Results: TexMACS, OpTmizer, SCGM, ABS-001 and StemXVivo demonstrated equal or inferior NK cell expansion kinetics compared with standard medium, but expansion was markedly superior with AIM V + 5% Immune Cell Serum Replacement (ICSR; mean 5448 vs. 2621-fold expansion in 14 days). Surprisingly, NK cells expanded in AIM V + ICSR also showed increased cytotoxicity, tumor necrosis factor α secretion and DNAM-1, NKG2D, NKp30, FasL, granzyme B and perforin expression. Lot-to-lot variability was minimal. Glucose and glutamine consumption were inversely related to lactate and ammonia production. Discussion: The AIM V + ICSR SFM system supports excellent ex vivo expansion of clinical-grade NK cells with the phenotype and function needed for adoptive immunotherapy.
KW - cancer immunotherapy
KW - natural killer cells
KW - serum-free medium
UR - http://www.scopus.com/inward/record.url?scp=85083006007&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2020.02.002
DO - 10.1016/j.jcyt.2020.02.002
M3 - Article
C2 - 32278551
AN - SCOPUS:85083006007
SN - 1465-3249
VL - 22
SP - 322
EP - 328
JO - Cytotherapy
JF - Cytotherapy
IS - 6
ER -